Curevax

company

About

Dedicated to the fight against melanoma through the development of safer and more effective immunotherapeutic vaccines.

  • 1 - 10

Details

Last Funding Type
Seed
Last Funding Money Raised
$2.87M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2006
Number Of Employee
1 - 10
Operating Status
Active

CureVax is an emerging cancer treatment method in which a patient’s tumor cells are sampled, grown in the laboratory, and burst open in a very specific way in order to expose that specific cancer’s vulnerabilities. These processed shreds of the tumor cells are then injected back into the patient, stimulating his or her immune system to attack the cancer. A virus-lysed tumor cell vaccine is an active immunotherapeutic agent against tumors in patients. Tumor cells are removed from a patient, the cells are cultured in the laboratory and infected with live vaccinia virus—the active component of the vaccine that eradicated smallpox. During incubation, viral oncolysis occurs, in which the virus enters the tumor cells and breaks them open, spilling their contents, in a process known as lysis. The resulting viral oncolysate has lost the ability to grow as a tumor, but can be recognized by the patient’s immune system as the tumor. After extraction and processing, the viral oncolysate may be injected back into the patient to stimulate the immune response.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2.87M
Curevax has raised a total of $2.87M in funding over 2 rounds. Their latest funding was raised on Dec 1, 2006 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 1, 2006 Seed $2.87M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Curevax is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Seed